Mistletoe and Gemcitabine in Patients with Advanced Cancer: A Model for the Phase I Study of Botanicals and Botanical-Drug Interactions in Cancer Therapy
Free accessOtherFirst published online December, 2003
Mistletoe and Gemcitabine in Patients with Advanced Cancer: A Model for the Phase I Study of Botanicals and Botanical-Drug Interactions in Cancer Therapy
Plant extracts of the European mistletoe (MTE), Viscum album, the most widely used cancer treatment in Germany, have been used in European countries as sole intervention or as adjunct to conventional cancer therapies for more than 80years. Preclinical data suggest immunostimulatory and cytotoxic effects of MTE. While the clinical efficacy of MTE in cancer is being investigated, toxicity and potential interactions of MTE with standard chemotherapeutic agents are unknown. Gemcitabine is an approved antimetabolite chemotherapeutic agent effective as single agent in patients with solid tumors (ST). The documented metabolism and pharmacokinetics of gemcitabine make this agent well suited for the study of botanical-chemotherapy drug interactions (BDIA) in cancer. Based on reports of altered drug metabolism associated with botanical preparations, research into BDIA has intensified. The phase I, 2-stage, dose-escalation study outlined here will test MTE with gemcitabine as a paradigm for the phase I investigation of botanical-drug combination treatments in patients with advanced ST. The protocol including the following components has been reviewed and approved by the National Cancer Institute Institutional Review Board (IRB), the National Naval Medical Center IRB, and the Navy Clinical Investigation Program (study 02-074): (1) use of a standardized MTE, approved by the Food and Drug Administration for investigational use; (2) independent verification of key MTE components considered biologically active; (3) identification of contaminants and adulterants; (4) pharmacokinetics of gemcitabine and its principal metabolites before and upon exposure to MTE; (5) safety and toxicity data collection; (6) assays of plasma ML antibody production in vivo; and (7) pharmacodynamic studies of the botanical-drug combination.
References
1.
1. Steiner R. Geisteswissenschaft und Medizin. 6th ed. Dornach: Rudolf Steiner Verlag; 1985.
2.
2. Kiene H. Klinische Studien zur Misteltherapie karzinomatoeser Erkrankungen, Eine Uebersicht. Therapeutikon. 1990;3:347-353.
3.
3. Hauser SP. Iscador-Mistelpraeparat zur Krebsbekaempfung Dokumentation Nr. 10. Schweiz Rundschau Med Prax. 1988;77(4):69-74.
4.
4. Kleijnen J, Knipschild P. Mistletoe treatment for cancer: review of controlled trials. Phytomedicine. 1994;1:255-260.
5.
5. Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med. 2001;7:57-66, 68-72, 74-56, passim.
6.
6. Hostanska K, Hajto T, Spagnoli GC, Fischer J, Lentzen H, Herrmann R. A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun. 1995;14:295-304.
7.
7. Stein G, Berg PA. Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro. Eur J Clin Pharmacol. 1994;47(1):33-38.
8.
8. Rentea R, Lyon E, Hunter R. Biologic properties of Iscador: a Viscum album preparation I. Hyperplasia of the thymic cortex and accelerated regeneration of hematopoietic cells following X-irradiation. Lab Invest. 1981;44(1):43-48.
9.
9. Beuth J, Ko HL, Tunggal L, et al. Thymocyte proliferation and maturation in response to galactoside-specific mistletoe lectin-1. In Vivo. 1993;7:407-410.
10.
10. Kuttan G. Tumoricidal activity of mouse peritoneal macrophages treated with Viscum album extract. Immunol Invest. 1993;22:431-440.
11.
11. Hamprecht K, Handgretinger R, Voetsch W, Anderer FA. Mediation of human NK-activity by components in extracts of Viscum album. Int J Immunopharmacol. 1987;9:199-209.
12.
12. Hajto T, Lanzrein C. Natural killer and antibody-dependent cell-mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album-treated breast cancer patients. Oncology. 1986;43:93-97.
13.
13. Samtleben RHT, Hostanska K. Mistletoe lectins as immunostimulants (chemistry, pharmacology and clinic). In: Wagner H, ed. Immunomodulatory Agents From Plants. Basel, Switzerland: Birkhauser Verlag; 1999:223-241.
14.
14. Lee RT, Gabius HJ, Lee YC. Ligand binding characteristics of the major mistletoe lectin. J Biol Chem. 1992;267:23722-23727.
15.
15. Bussing A. Mistletoe therapy and immunological research. Anticancer Drugs. 1997;8(suppl 1):S65-S65.
16.
16. Stein GM, Berg PA. Mistletoe extract-induced effects on immunocompetent cells: in vitro studies. Anticancer Drugs. 1997; 8(suppl 1):S39-S42.
17.
17. Gabius HJ, Andre S, Kaltner H, Siebert HC, von der Lieth CW, Gabius S. [The mistletoe myth—claims, reality and provable perspectives]. Z Arztl Fortbild (Jena).1996;90:103-110.
18.
18. Franz H. Mistletoe lectins and their A and B chains. Oncology. 1986;43(suppl 1):23-34.
19.
19. Elsasser-Beile U, Voss M, Schuhle R, Wetterauer U. Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro. J Clin Lab Anal. 2000;14:255-259.
20.
20. Elsasser-Beile U, Lusebrink S, Grussenmeyer T, Wetterauer U, Schultze-Seemann W. Comparison of the effects of various clinically applied mistletoe preparations on peripheral blood leukocytes. Arzneimittelforschung. 1998;48:1185-1189.
21.
21. Ribereau-Gayon G, Dumont S, Muller C, Jung ML, Poindron P, Anton R. Mistletoe lectins I, II and III induce the production of cytokines by cultured human monocytes. Cancer Lett. 1996; 109(1-2):33-38.
22.
22. Hajto T, Hostanska K, Weber K, et al. Effect of a recombinant lectin, Viscum album agglutinin on the secretion of interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cell-mediated cytotoxicity of rat splenocytes in vitro and in vivo. Nat Immun. 1998;16(1):34-46.
23.
23. Hajto T, Hostanska K, Frei K, Rordorf C, Gabius HJ. Increased secretion of tumor necrosis factors alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to betagalactoside-specific lectin from clinically applied mistletoe extract. Cancer Res. 1990;50:3322-3326.
24.
24. Pae HO, Seo WG, Oh GS, et al. Potentiation of tumor necrosis factor-alpha-induced apoptosis by mistletoe lectin. Immunopharmacol Immunotoxicol. 2000;22:697-709.
25.
25. Bussing A, Stein GM, Pfuller U, Schietzel M. Induction of Fas ligand (CD95L) by the toxic mistletoe lectins in human lymphocytes. Anticancer Res. 1999;19:1785-1790.
26.
26. Kuttan G, Kuttan R. Reduction of leukopenia in mice by “viscum album” administration during radiation and chemotherapy. Tumori. 1993;79(1):74-76.
27.
27. Weber K, Mengs U, Schwarz T, Becker H, Lentzen H. Stimulation of neutropoiesis by a special standardized mistletoe preparation after cyclophosphamide chemotherapy in mice. Arzneimittelforschung. 1996;46:1174-1178.
28.
28. Savoie A, Lavastre V, Pelletier M, Hajto T, Hostanska K, Girard D. Activation of human neutrophils by the plant lectin Viscum album agglutinin-I: modulation of de novo protein synthesis and evidence that caspases are involved in induction of apoptosis. J Leukoc Biol. 2000;68:845-853.
29.
29. Stettin A, Schultze JL, Stechemesser E, Berg PA. Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro. Klin Wochenschr. 1990;68:896-900.
30.
30. Stein GM, Berg PA. Characterisation of immunological reactivity of patients with adverse effects during therapy with an aqueous mistletoe extract. Eur J Med Res. 1999;4:169-177.
31.
31. Stein GM, Pfuller U, Berg PA. Recognition of different antigens of mistletoe extracts by anti-mistletoe lectin antibodies. Cancer Lett. 1999;135:165-170.
32.
32. Lenartz D, Dott U, Menzel J, Schierholz JM, Beuth J. Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res. 2000;20:2073-2076.
33.
33. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer. 2001;37(1):23-31.
34.
34. Eggermont AM KU, Ruiter DJ, Suciu S. European Organization of Research and Treatment of Cancer Melanoma Group trial experience with more than 2,000 patients, evaluating adjuvant treatment with low or intermediate doses of interferon alpha-2b. Paper presented at: American Society of Clinical Oncology Annual Meeting; 2001; San Francisco.
35.
35. Heiny BM, Albrecht V, Beuth J. Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract. Anticancer Res. 1998;18:583-586.
36.
36. Heiny BM, Beuth J. Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res. 1994;14:1339-1342.
37.
37. Friess H, Buchler M, Ebert M, Malfertheiner P, Dennler HJ, Beger HG. Treatment of advanced pancreatic cancer with high-dose octreotide. Int J Pancreatol. 1993;14:290-291.
38.
38. Gorter RW, van Wely M, Reif M, Stoss M. Tolerability of an extract of European mistletoe among immunocompromised and healthy individuals. Altern Ther Health Med. 1999;5(6):37-44, 47-38.
39.
39. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs. 2001;61:2163-2175.
40.
40. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7:2182-2194.
41.
41. Harkey MR, Henderson GL, Gershwin ME, Stern JS, Hackman RM. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr. 2001;73:1101-1106.
42.
42. Liberti LE, Der Marderosian A. Evaluation of commercial ginseng products. J Pharm Sci. 1978;67:1487-1489.
43.
43. Wurglics M, Westerhoff K, Kaunzinger A, et al. Comparison of German St. John’s wort products according to hyperforin and total hypericin content. J Am Pharm Assoc (Wash).2001; 41:560-566.
44.
44. Edwards DJ, Draper EJ. Variations in alkaloid content of herbal products containing goldenseal. J Am Pharm Assoc (Wash DC). 2003;43:419-423.
45.
45. Shohet D, Wills RB, Stuart DL. Valepotriates and valerenic acids in commercial preparations of valerian available in Australia. Pharmazie. 2001;56:860-863.
46.
46. Bergonzi MC, Bilia AR, Gallori S, Guerrini D, Vincieri FF. Variability in the content of the constituents of Hypericum perforatum L. and some commercial extracts. Drug Dev Ind Pharm. 2001;27:491-497.
47.
47. Guns ES, Goldenberg SL, Brown PN. Mass spectral analysis of PC-SPES confirms the presence of diethylstilbestrol. Can J Urol. 2002;9:1684-1688; discussion, 1689.
48.
48. White J. PC-SPES—a lesson for future dietary supplement research. J Natl Cancer Inst. 2002;94:1261-1263.
50. Kaye SB. Gemcitabine: current status of phase I and II trials. J Clin Oncol. 1994;12:1527-1531.
51.
51. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2’,2’-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 1994; 86:1530-1533.
52.
52. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2’-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12(1):29-34.
53.
53. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in nonsmall-cell lung cancer: a phase II study. J Clin Oncol. 1994; 12:1535-1540.
54.
54. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996;7:347-353.
55.
55. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997;15:3394-3398.
56.
56. von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of gemcitabine in ovarian cancer. Ann Oncol. 1999;10:853-855.
57.
57. Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol. 1996; 63(1):89-93.
58.
58. Fossella FV, Lippman SM, Shin DM, et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I doseescalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol. 1997;15(1): 310-316.
59.
59. Begbie SD, Hui R, Levi JA, et al. Initial experience with gemcitabine for non-small cell lung cancer in Australia. Proc Annu Meet Am Soc Clin Oncol.1995; 14:A1172-A1172.
60.
60. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
61.
61. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology. 2002; 62(1):2-8.
62.
62. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997;15:3441-3445.
63.
63. Underhill CR, Parnis FX, Highley MS, et al. Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Anticancer Drugs. 2001;12: 647-652.
64.
64. Goedhals L. BWR. A phase II study of gemcitabine in advanced cervix carcinoma: final data; 1996.
65.
65. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491-498.
66.
66. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol. 1992; 10:406-413.
67.
67. Lund B, Kristjansen PE, Hansen HH. Clinical and preclinical activity of 2’,2’-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev. 1993;19:45-55.
68.
68. Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study. Invest New Drugs. 1994;12:111-119.
69.
69. Poplin EA, Corbett T, Flaherty L, et al. Difluorodeoxycytidine (dFdC)—gemcitabine: a phase I study. Invest New Drugs. 1992; 10:165-170.
70.
70. Anderson H, Thatcher N, Walling J, Hansen H. A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer. 1996;74:460-462.
71.
71. Kassem B, Miketic LM, Landreneau RJ. Phase I study of gemcitabine given weekly as short infusion. Proc Am Soc Clin Oncol.1995;14:383-383.
72.
72. Martin C, Lund B, Anderson H, Thatcher N. Gemcitabine: once-weekly schedule active and better tolerated than twiceweekly schedule. Anticancer Drugs. 1996;7:351-357.
73.
73. Touroutoglou N, Gravel D, Raber MN, PlunkettW, Abbruzzese JL. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol. 1998;9:1003-1008.
74.
74. Pollera CF, Ceribelli A, Crecco M, Oliva C, Calabresi F. Prolonged infusion gemcitabine: a clinical phase I study at low-(300 mg/m2) and high-dose (875 mg/m2) levels. Invest New Drugs. 1997;15:115-121.
